Arcus Biosciences (NYSE: RCUS) shareholder files Rule 144 to sell 5,000 shares

Rhea-AI Filing Summary

Arcus Biosciences, Inc. shareholder Alexander Azoy has filed a Rule 144 notice to sell 5000 shares of the company’s common stock through E*TRADE Financial Corporation on or about 12/16/2025. The planned sale has an aggregate market value of 109500, and the notice lists 122856086 Arcus common shares outstanding on the New York Stock Exchange.

The securities to be sold were acquired on 12/15/2025 through vesting of restricted stock grants originally awarded on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 in exchange for services rendered, covering 1062, 1282, 2213, and 4275 shares respectively. The filing also reports that Azoy sold Arcus common stock in three prior transactions over the past three months, including 1900 shares on 11/26/2025 for gross proceeds of 49400 and 2831 shares on 09/29/2025 for gross proceeds of 36803.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	5000	109500	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 3/8/2022	Arcus Biosciences, Inc.			1062	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2023	Arcus Biosciences, Inc.			1282	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2024	Arcus Biosciences, Inc.			2213	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2025	Arcus Biosciences, Inc.			4275	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Alexander Azoy 3928 Point Eden Way Hayward CA 94545	Common Stock	11/26/2025	1900	49400
Alexander Azoy 3928 Point Eden Way Hayward CA 94545	Common Stock	09/29/2025	2831	36803
Alexander Azoy 3928 Point Eden Way Hayward CA 94545	Common Stock	09/05/2025	1579	18758.05

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Arcus Biosciences (RCUS) disclose in this Rule 144 filing?

The filing reports that shareholder Alexander Azoy has filed a Rule 144 notice to sell 5000 shares of Arcus Biosciences common stock on or about 12/16/2025 through E*TRADE Financial Corporation.

How many Arcus Biosciences (RCUS) shares are planned for sale and where will they trade?

The notice covers a proposed sale of 5000 common shares of Arcus Biosciences, Inc., to be sold through E*TRADE Financial Corporation on the NYSE, as listed in the filing.

How were the Arcus Biosciences (RCUS) shares being sold under Rule 144 acquired?

The shares were acquired on 12/15/2025 via vesting of restricted stock granted by Arcus Biosciences on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025, covering 1062, 1282, 2213, and 4275 shares respectively, as compensation for services rendered.

What prior Arcus Biosciences (RCUS) share sales by this holder are disclosed?

The filing lists three recent sales by Alexander Azoy: 1579 shares on 09/05/2025 for gross proceeds of 18758.05, 2831 shares on 09/29/2025 for 36803, and 1900 shares on 11/26/2025 for 49400.

How many Arcus Biosciences (RCUS) shares are outstanding according to this notice?

The Rule 144 notice lists 122856086 shares of Arcus Biosciences common stock outstanding.

What is the aggregate market value of the Arcus Biosciences shares to be sold?

The proposed sale of 5000 Arcus Biosciences common shares has an aggregate market value of 109500, as stated in the filing.